Peppermint Venture Partners

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.

Labforward is a company dedicated to enhancing laboratory productivity and efficiency through innovative digital tools. It offers products such as Labfolder, a user-friendly electronic laboratory notebook that helps scientists record, organize, and share data. Additionally, Labforward's IoT platform, Laboperator, enables remote control and monitoring of laboratory equipment, integrates various systems, and automates workflows. By addressing the fragmented nature of laboratory data management, Labforward connects data silos, thus reducing error-prone data transfers and streamlining laboratory operations. The company focuses on the common core of data management needs across diverse fields, including life sciences, chemical synthesis, analytics, and quality control, ensuring that its solutions cater to the specific requirements of various laboratory activities.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, that specializes in innovative solutions for glaucoma management and treatment. Founded in 2010, the company focuses on advancing care for glaucoma patients by developing disruptive technologies. Its flagship product, Eyemate, is an implantable micro sensor designed for the continuous telemetric measurement of intraocular pressure. This biocompatible device can be permanently implanted in the patient's eye without affecting vision or overall well-being, allowing for improved monitoring and management of glaucoma. Through this technology, Implandata aims to enhance the quality of care for patients, families, and caregivers, addressing an important and underserved area in glaucoma therapy.

Miracor Medical is a medical device company that specializes in developing clinical devices aimed at treating severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company is known for its PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion technology. This innovative system is designed to assist cardiac surgeons in treating patients experiencing myocardial infarction during coronary artery bypass grafting procedures. By enhancing microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size, improve cardiac function, and potentially decrease the likelihood of heart failure following acute myocardial infarction.

Miracor Medical is a medical device company that specializes in developing clinical devices aimed at treating severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company is known for its PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion technology. This innovative system is designed to assist cardiac surgeons in treating patients experiencing myocardial infarction during coronary artery bypass grafting procedures. By enhancing microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size, improve cardiac function, and potentially decrease the likelihood of heart failure following acute myocardial infarction.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.

Emperra E-Health Technologies is a German company based in Potsdam, established in 2008, that specializes in the development of telemedical products aimed at managing diabetes. The company focuses on creating GSM and web-based systems for tracking, monitoring, and transmitting crucial diagnostic and therapeutic data related to diabetes. Its innovative diabetes monitoring solutions include a Bluetooth-enabled insulin pen and a wireless blood glucose meter, which allow healthcare professionals to effectively monitor insulin doses, blood sugar levels, and carbohydrate intake in patients. By facilitating real-time data transmission, Emperra enhances the ability of doctors and nurses to manage diabetes care efficiently.

CEVEC Pharmaceuticals GmbH is a biopharmaceutical company based in Cologne, Germany, specializing in the production of therapeutic proteins and monoclonal antibodies using a unique human cell-based expression system. Founded in 2001, CEVEC has developed the CAP-GO platform, which allows for the efficient production of complex, glycosylated proteins that are challenging to express using conventional cell lines. This platform includes optimized expression vectors, serum- and animal component-free cell line generation, and stable pool generation for recombinant proteins. Additionally, CEVEC offers the CAP-GT platform, facilitating large-scale production of gene therapy vectors, including Lentiviral, Adenoviral, and AAV types. The company also provides contract manufacturing services and has established a strategic collaboration with BioLamina AB, enhancing its capabilities in the biopharmaceutical sector.

Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in developing innovative solutions for liver function assessment. The company's flagship product, the LiMAx test, is a breath analysis device that enables real-time measurement of liver function in patients with liver failure. This easy-to-use bedside system includes a medical device, breath masks, and a diagnostic drug, allowing clinicians to accurately quantify liver function capacity. The LiMAx test is utilized in various clinical applications, such as evaluating liver function prior to and following liver transplantation, planning for living donor liver resection, and assessing conditions like liver cirrhosis. With its technology already benefiting thousands of patients, Humedics is actively expanding its global operations to enhance patient outcomes through tailored medical treatment.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, that specializes in innovative solutions for glaucoma management and treatment. Founded in 2010, the company focuses on advancing care for glaucoma patients by developing disruptive technologies. Its flagship product, Eyemate, is an implantable micro sensor designed for the continuous telemetric measurement of intraocular pressure. This biocompatible device can be permanently implanted in the patient's eye without affecting vision or overall well-being, allowing for improved monitoring and management of glaucoma. Through this technology, Implandata aims to enhance the quality of care for patients, families, and caregivers, addressing an important and underserved area in glaucoma therapy.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.

CAP-CMV GmbH develops vaccines for protection against human Cytomegalovirus (HCMV) infection.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, that specializes in innovative solutions for glaucoma management and treatment. Founded in 2010, the company focuses on advancing care for glaucoma patients by developing disruptive technologies. Its flagship product, Eyemate, is an implantable micro sensor designed for the continuous telemetric measurement of intraocular pressure. This biocompatible device can be permanently implanted in the patient's eye without affecting vision or overall well-being, allowing for improved monitoring and management of glaucoma. Through this technology, Implandata aims to enhance the quality of care for patients, families, and caregivers, addressing an important and underserved area in glaucoma therapy.

As of May 13, 2005, weblicon technologies AG was acquired by Synchronica Software GmbH. Weblicon technologies AG is based in Berlin, Germany and develops and markets web-based applications such as online organizer, featuring online calendaring, contact management and e-mail. The company’s product can be integrated into existing networks of servers, applications and databases and is platform-independent and customizable. Major clients are telecommunication companies, portals as well as service providers.